Press Releases

SUNNYVALE, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 first quarter before the market opens on Friday, August 13, 2021.
July 29, 2021
Dr. Valerie Montgomery Rice and Peter Taylor Join 23andMe’s Board as the Company Sets to Accelerate Personalized Healthcare Based on Human Genetics SUNNYVALE, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company,
June 21, 2021
Combined Company to Trade on Nasdaq Under Ticker “ME” Commencing June 17 SUNNYVALE, Calif. and NEW YORK, June 16, 2021 (GLOBE NEWSWIRE) -- 23andMe, Inc., a leading consumer genetics and research company, and VG Acquisition Corp. (NYSE: VGAC), a special purpose acquisition company sponsored by
June 16, 2021
Brings scientific expertise in functional genomics combined with strong investor relations leadership in the pharmaceutical industry SUNNYVALE, Calif. , June 2, 2021 /PRNewswire/ -- 23andMe Inc., a leading consumer genetics and research company, today announced that D. Wade Walke , Ph.D.
June 2, 2021
23andMe is a leading consumer genetics and research company that offers a personalized health and wellness experience and has built a premier genetic database to unlock insights leading to the rapid discovery of promising new targets for drug development Transaction will provide the capital to fund
February 4, 2021
Print Page
RSS Feeds
Email Alerts
Contact IR